Drugs / Nerinetide
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04462536 | Dec 2020 → Aug 2023 | ischemic stroke | NoNO Inc. | Completed | Missed primary |
| Phase 3 | NCT02930018 | Mar 2017 → Nov 2019 | ischemic stroke | NoNO Inc. | Completed | Missed primary |
| Phase 3 | NCT02315443 | Mar 2015 → Mar 2023 | brain ischemia | NoNO Inc. | Completed | Missed primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nerinetide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02930018 ↗ |
| Known as | NA-1 | “Nerinetide (NA-1) is being developed as an emergency drug aimed at reducing global disability in patients with acute cerebral ischemia if administered early after symptom onset.” NCT02315443 ↗1“Nerinetide (NA-1), 2.6 mg/kg” NCT02930018 ↗ |
| Action | Inhibit | “nerinetide, an eicosapeptide that interferes with post-synaptic density protein 95” PMID 39955119 ↗ Feb 2025 |
| Modality | Peptide | “Nerinetide, an eicosapeptide that interferes with post-synaptic density protein 95” PMID 32087818 ↗ Feb 2020 |
| Route | Intravenous | “Single intravenous infusion of nerinetide over 10 ± 1 minutes” NCT02930018 ↗ |